Lexaria Celebrates its 70th Patent Award

New patents awarded in the US, Canada, and Europe IP protection for treatments for Epilepsy, Diabetes, and Hypertension Kelowna, British Columbia – TheNewswire - October 28, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property (“ IP ”) granted to the Company as a result of its ongoing research and development (“ R&D ”) programs. The expansion of our IP is recognized and achieved, in part, through new international patent awards. “Our IP is our most valuable asset that, as it grows and strengthens, supports our ongoing and accelerating business development programs,” said Richard Christopher, CEO of Lexaria. “Lexaria has built a world-class portfolio of patent-protected IP across most of the world’s biggest pharmaceutical markets and will continue to build on this in the future.” US Patent 12,691,163: this is our 3 rd US patent granted in Family #27 - Compositions and Methods for Treating Diabetes - and our 5 th overall in this family including 2 granted in Australia. This patent was granted on July 28, 2026 and covers DehydraTECH proces

Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes